Add-on trimebutine-maleate does not improve tolerability or eradication in bismuth quadruple therapy for Helicobacter pylori

Table 2 Treatment-emergent adverse events during 14-day bismuth quadruple therapy, n (%)

Event	Control (n = 66)	Trimebutine (n = 66)	P value
Any adverse event	34 (51.5)	33 (50.0)	> 0.999
Nausea	20 (30.3)	22 (33.3)	0.852
Diarrhea/loose stool	7 (10.6)	13 (19.7)	0.224
Dizziness	5 (7.6)	1 (1.5)	0.208
Dyspepsia/bloating	5 (7.6)	3 (4.5)	0.718
Dysgeusia (bitter/metallic)	3 (4.5)	4 (6.1)	> 0.999
Headache	3 (4.5)	3 (4.5)	> 0.999
Epigastric discomfort/heartburn	3 (4.5)	4 (6.1)	> 0.999
Asthenia/fatigue	4 (6.1)	3 (4.5)	> 0.999
Vomiting	3 (4.5)	1 (1.5)	0.619
Dark stool (bismuth-related)	3 (4.5)	6 (9.1)	0.492
Abdominal pain	1 (1.5)	2 (3.0)	> 0.999
Anorexia	0 (0.0)	1 (1.5)	> 0.999
Treatment discontinuation due to AE	7 (10.6)	7 (10.6)	> 0.999
Serious adverse event	0 (0.0)	0 (0.0)

Patients could report more than one type of adverse event; percentages therefore do not sum to 100. P values from Fisher’s exact test. AE: Adverse event.